Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies

Yufan Bio, a Xi'an clinical-stage CAR-T company, partnered with Abound Bio of Pittsburgh to develop novel CAR-T technologies. The two companies will explore the use of HPK1 (hematopoietic progenitor kinase 1) inhibitors to make CAR-T therapies more effective. HPK1 has been shown to promote CAR-T exhaustion in research done by Xuebin Liao , PhD, Professor of Pharmaceutical Science at Tsinghua University and a Yufan co-founder. Yufan is working to inhibit HPK1 via gene knockout or small-molecule inhibitors. More details.... Share this with colleagues: // //